Published in World J Gastroenterol on August 07, 2012
Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol (2014) 2.27
Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol (2014) 1.16
Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol (2012) 1.15
Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. J Exp Med (2015) 0.96
Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-κB and MAPK signaling inactivation. Int Immunopharmacol (2014) 0.94
Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis. Aliment Pharmacol Ther (2014) 0.89
The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review. Dig Dis Sci (2014) 0.89
Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Ann Gastroenterol (2014) 0.88
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (review). Int J Oncol (2014) 0.86
The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol Sci (2014) 0.86
Thrombin drives tumorigenesis in colitis-associated colon cancer. Cancer Res (2014) 0.84
Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One (2013) 0.83
Inflammation increases NOTCH1 activity via MMP9 and is counteracted by Eicosapentaenoic Acid-free fatty acid in colon cancer cells. Sci Rep (2016) 0.83
A clinical perspective on the role of chronic inflammation in gastrointestinal cancer. Clin Exp Gastroenterol (2014) 0.81
Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review. Curr Treat Options Oncol (2014) 0.81
High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. Oncoimmunology (2015) 0.80
The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch (2015) 0.80
Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review. World J Gastroenterol (2015) 0.80
Infection with murine norovirus 4 does not alter Helicobacter-induced inflammatory bowel disease in Il10(-/-) mice. Comp Med (2014) 0.80
STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer. World J Gastroenterol (2014) 0.80
Loss of PHLPP protects against colitis by inhibiting intestinal epithelial cell apoptosis. Biochim Biophys Acta (2015) 0.80
Linking estrogen receptor β expression with inflammatory bowel disease activity. Oncotarget (2015) 0.79
The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut (2016) 0.78
Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: where are we now in the era of the next generation proteomics? World J Gastroenterol (2014) 0.78
Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies. World J Gastrointest Pharmacol Ther (2016) 0.78
Possible mechanisms of action of mushroom-derived glucans on inflammatory bowel disease and associated cancer. Ann Transl Med (2014) 0.78
Therapeutic actions of melatonin on gastrointestinal cancer development and progression. Transl Gastrointest Cancer (2013) 0.78
Alpinetin attenuates inflammatory responses by suppressing TLR4 and NLRP3 signaling pathways in DSS-induced acute colitis. Sci Rep (2016) 0.78
Blockade of MK2 is protective in inflammation-associated colorectal cancer development. Int J Cancer (2015) 0.78
Genomic instability and cellular stress in organ biopsies and peripheral blood lymphocytes from patients with colorectal cancer and predisposing pathologies. Oncotarget (2015) 0.77
Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol (2016) 0.77
The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer. Oncotarget (2016) 0.76
The Aryl Hydrocarbon Receptor is a Repressor of Inflammation-associated Colorectal Tumorigenesis in Mouse. Ann Surg (2016) 0.76
The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c-Myc and C/EBPβ rather than Enterotoxigenic Bacteroides fragilis Infection. Oxid Med Cell Longev (2016) 0.76
Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer. Cancer Res Front (2016) 0.76
Advanced endoscopic imaging for surveillance for dysplasia and colorectal cancer in inflammatory bowel disease: could the pathologist be further helped? Saudi J Gastroenterol (2014) 0.75
Characteristics and prognosis of colorectal cancer associated with rheumatic disease. Int Surg (2015) 0.75
Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World J Gastroenterol (2016) 0.75
Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis. Gastroenterol Res Pract (2016) 0.75
Altered expression of caspases-4 and -5 during inflammatory bowel disease and colorectal cancer: Diagnostic and therapeutic potential. Clin Exp Immunol (2015) 0.75
Mucosal healing in ulcerative colitis: surveillance or colectomy? Ann Gastroenterol (2013) 0.75
Anal Canal Adenocarcinoma in a Patient with Longstanding Crohn's Disease Arising From Rectal Mucosa that Migrated From a Previously Treated Rectovaginal Fistula. Am J Case Rep (2016) 0.75
Helicteric Acid, Oleanic Acid, and Betulinic Acid, Three Triterpenes from Helicteres angustifolia L., Inhibit Proliferation and Induce Apoptosis in HT-29 Colorectal Cancer Cells via Suppressing NF-κB and STAT3 Signaling. Evid Based Complement Alternat Med (2017) 0.75
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget (2016) 0.75
Associations of the A66G Methionine Synthase Reductase Polymorphism in Colorectal Cancer: A Systematic Review and Meta-Analysis. Biomark Cancer (2015) 0.75
A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. J Gastroenterol (2016) 0.75
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 6.87
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut (2010) 6.34
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology (2003) 5.11
Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology (2003) 4.64
Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer (2001) 4.61
Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 4.61
Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15
Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut (1988) 3.66
High frequency of early colorectal cancer in inflammatory bowel disease. Gut (2008) 3.46
Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology (1994) 3.44
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39
Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet (1994) 3.22
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Cancer: Inflaming metastasis. Nature (2009) 3.09
Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis (2005) 3.01
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol (2005) 2.98
New IBD genetics: common pathways with other diseases. Gut (2011) 2.95
Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut (2004) 2.92
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol (1995) 2.73
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology (1989) 2.66
Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology (2006) 2.63
ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc (2006) 2.63
Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet (1990) 2.58
DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology (1992) 2.48
Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology (1979) 2.48
Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology (1995) 2.44
How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc (2000) 2.42
Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther (2000) 2.25
Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med (2002) 2.24
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med (2001) 2.22
Cancer in inflammatory bowel disease. World J Gastroenterol (2008) 2.12
Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther (2003) 2.05
Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol (2000) 2.03
Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy (2005) 1.95
Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene (2010) 1.88
Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology (2009) 1.85
Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol (2008) 1.79
Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol (2005) 1.79
Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet (2001) 1.72
Retracted Confocal chromoscopic endomicroscopy is superior to chromoscopy alone for the detection and characterisation of intraepithelial neoplasia in chronic ulcerative colitis. Gut (2008) 1.68
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc (2002) 1.65
Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology (2001) 1.63
Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut (2004) 1.63
Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy (2007) 1.60
Trends in incidence rates of ulcerative colitis and Crohn's disease. Dig Dis Sci (1984) 1.57
Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol (2004) 1.56
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51
Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology (2000) 1.50
Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. Digestion (2006) 1.49
SCLEROSING CHOLANGITIS; REVIEW OF RECENT CASE REPORTS AND ASSOCIATED DISEASES AND FOUR NEW CASES. Am J Surg (1965) 1.47
The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol (1999) 1.40
Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology (1999) 1.35
Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut (2003) 1.32
Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's disease. Gut (2009) 1.31
Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis (2006) 1.31
The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol (2002) 1.30
Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol (2008) 1.30
SCLEROSING CHOLANGITIS. ASSOCIATION WITH REGIONAL ENTERITIS. JAMA (1964) 1.27
Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am (2006) 1.20
The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology (1997) 1.19
Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum (2002) 1.14
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.14
Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum (1997) 1.13
Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am (2006) 1.05
The pathogenesis of inflammatory polyps. Dis Colon Rectum (1987) 1.03
Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol (2008) 0.96
Colorectal cancer in inflammatory bowel disease. Gut Liver (2008) 0.94
Inflammatory bowel disease and colon cancer. Cancer (1992) 0.90
Chromosomal and microsatellite instability of adenocarcinomas and dysplastic lesions (DALM) in ulcerative colitis. Diagn Mol Pathol (2006) 0.87
Colonoscopy, tumors, and inflammatory bowel disease - new diagnostic methods. Endoscopy (2006) 0.87
Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Can J Gastroenterol (2007) 0.87
Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis. J Gastroenterol Hepatol (2005) 0.86
Colorectal cancer in inflammatory bowel disease: molecular and clinical features. Gastroenterol Clin North Am (2002) 0.78
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut (2010) 6.34
European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis (2013) 3.01
Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut (2011) 2.00
A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures. Clin Gastroenterol Hepatol (2007) 1.71
Development and validation of a nurse-assessed patient comfort score for colonoscopy. Gastrointest Endosc (2013) 1.52
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis (2008) 1.09
Quality in colonoscopy: European perspectives and practice. Expert Rev Gastroenterol Hepatol (2013) 1.00
High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme. J Med Screen (2011) 0.93
Haemorrhagic radiation proctitis: endoscopic severity may be useful to guide therapy. Int J Colorectal Dis (2003) 0.89
Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing? Digestion (2012) 0.86
Improving the quality of colonoscopy. Gastrointest Endosc (2012) 0.75
Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc (2008) 0.75